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ABSTRACT
Objectives: In 2005, in Ontario, Canada, newborns were
only screened for phenylketonuria (PKU) and hypothy-
roidism. Tandem mass spectrometry (MS/MS) has since been
implemented as a new screening technology because it can
screen for PKU and many other diseases simultaneously. We
estimated the cost-effectiveness of using this technology to
expand the Ontario newborn screening program to screen
for each disease independently and for hypothetical bundles
of up to 21 metabolic diseases.
Methods: We constructed a decision-analytic model to esti-
mate the incremental costs and life-years of survival that can
be gained by screening or changing screening technologies.
Costs and health beneﬁts were estimated for a cohort of
babies born in Ontario in 1 year. Secondary sources and
expert opinion were used to estimate the test characteristics,
disease prevalence, treatment effectiveness, disease progres-
sion rates, and mortality. The London Health Sciences
Centre Case Costing Initiative, the Ontario Health Insurance
Plan Schedule, and the Ontario Drug Beneﬁts plan formulary
were used to estimate costs.
Results: Changing screening technologies, from the Guthrie
test to MS/MS, for PKU detection had an incremental cost of
$5,500,000 per life-year (LY) gained. We identiﬁed no dis-
eases for which the incremental cost of screening for just that
disease was less than $100,000 per LY gained. The incremen-
tal costs of screening ranged from $222,000 (HMG-CoA
lyase deﬁciency) to $142,500,000 (glutaric acidemia type II)
per LY gained. Screening for a bundle of diseases including
PKU and the 14 most cost-effective diseases to screen for cost
less than $70,000 per LY gained, and the incremental cost-
effectiveness of adding each of the 14 diseases to the bundle
was less than $100,000 per LY gained. The incremental cost
of adding the 15th most cost-effective disease was $309,400
per LY gained.
Conclusions: Early diagnosis and treatment of metabolic
disease is important to reduce disease severity and delay or
prevent the onset of the disease. Screening at birth reduces
the morbidity, mortality, and social burden associated with
the irreversible effects of disease on the population. Our
analysis suggests that the cost-efﬁciencies gained by using
MS/MS to screen for bundles of diseases rather than just
one  disease  are  sufﬁcient  to  warrant  consideration  of
an expanded screening program. It is, however, not cost-
effective to screen for all diseases that can be screened for
using this technology.
Keywords: cost-effectiveness, infant mortality, metabolic dis-
ease, newborn screening, policy.
Introduction
Screening newborns for metabolic disease began with
the screening of phenylketonuria (PKU) in the 1960s,
but technological advancements in many diagnostic
areas have led to the expansion of newborn screening
to include other inborn errors of metabolism (IEMs),
hemoglobinopathies, hormone deﬁciencies, enzyme
deﬁciencies, and hearing impairment. The use of
tandem mass spectrometry (MS/MS) in newborn
screening programs enables screening for 30 or more
metabolic disorders in a single analysis through the dif-
ferentiation and quantitation of multiple molecules
within a single specimen [1]. Elevation of one bio-
chemical marker may indicate that an infant has one of
several diseases, whereas the elevation of a combina-
tion of markers may lead physicians to a speciﬁc diag-
nosis more quickly.
At birth, most infants born with an IEM do not
have symptoms, although infants with some disorders
can present acutely within the ﬁrst few days of life.
Typically, these early presentations include metabolic
acidosis, hyperammonemia, hypoglycemia, or seizures.
Children with an IEM may present later in life with
physical or developmental delay, or metabolic crises.
Many IEMs can be treated by restrictive diets and
medications to greatly reduce and prevent mortality
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and morbidity, including mental retardation, severe
neurological disease, and physical deformity [2–9].
Early diagnosis and treatment generally improves
outcomes. Screening programs are often designed to
screen all infants for selected IEMs and identify those
children that require further investigation to obtain a
deﬁnitive diagnosis so that appropriate treatment can
begin before clinical symptoms develop. Although
each individual IEM is rare, summing the incidences of
the 21 metabolic diseases discussed in this article indi-
cates that these diseases collectively affect approxi-
mately 1 in every 3000 babies born in Ontario.
A dried blood spot (DBS) is collected from every
newborn in Ontario. Between 1965 and 2006 the DBS
was tested for abnormally high levels of phenylalanine
using the Guthrie bacterial inhibition assay [10], and a
positive PKU diagnosis was conﬁrmed by a quantita-
tive amino acid test on a second blood sample. Babies
with other diseases were diagnosed after clinical pres-
entation. Diagnosis of an IEM can be challenging
because the disorders are individually rare, symptoms
are often similar to those observed in acquired dis-
eases, and the metabolic decompensations are often
associated with intercurrent illnesses. Treatment
begins once a diagnosis is made; however, irreversible
damage may have already occurred.
The American College of Medical Genetics recom-
mends universal screening for 29 diseases, including
17 diseases that can be screened for using MS/MS
[11]. Nevertheless, determining which diseases are
appropriate for inclusion in screening programs is
controversial, involving both scientiﬁc and political
judgments [12–16]. In 2005, screening programs
across Canada varied widely, ranging from 2 to 29 dis-
eases, with only Ontario and New Brunswick screen-
ing for two diseases [17]. In 2000, two-thirds of US
states screened for six or fewer diseases [18], whereas
in 2005, every state screened for more than eight dis-
eases, and two-thirds of states screened for more than
30 diseases [19].
Model-based estimates for the cost-effectiveness of
screening are available for PKU [20–22], medium-
chain acyl-CoA dehydrogenase deﬁciency (MCADD)
[22–25], and some other IEMs [7,22,25,26] primarily
for the US and UK populations. This article presents
a decision-analytic model (Fig. 1) to evaluate the
Figure 1 Schematic diagram of decision
model. The small square represents the deci-
sion to implement a policy of newborn screen-
ing that includes a speciﬁc disease, or to
continue the status quo of not screening new-
borns for the disease. In the case of phenylke-
tonuria (PKU), the small square represents the
decision to change the screening technology to
mass spectrometry, or to continue with the
current technology; therefore, in the case of
PKU, the “No Screening” branch is replaced
with a “Screening” branch. Circles represent
chance events. The model divides babies into
two groups based on whether they have or do
not have the disease. In the expanded newborn
screening strategy, all babies are initially tested
for the disease; those who test positive have
their original sample retested. If  a baby has
two positive test results, their parents are
contacted, conﬁrmatory testing is initiated,
and prospective treatment begins. This model
assumes that the conﬁrmatory testing has a
sensitivity and a speciﬁcity of 100%. Babies
with the disease may have a severe or mild dis-
ease course, early or late onset, or may never
become affected by the disease. These disease-
speciﬁc variations were modeled by dividing
infants with the disease into Categories 1 and
2, and in some cases, category 3.
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incremental costs, health beneﬁts, and incremental
cost-effectiveness ratio for expanding the newborn
screening program in Ontario using MS/MS, to change
screening technologies for PKU, and to potentially
include 20 additional diseases that can be tested for at
birth.
Methods
All costs are presented in 2004 Canadian dollars.
Costs in other currencies were converted at the average
international exchange rate for August 2004. Costs
from other periods in time were adjusted using the
Canadian Health Care Price Index [27]. All costs and
beneﬁts were discounted at 3%. Important assump-
tions in this analysis are summarized in Table 1.
Incidence and Severity
Patients with each disease are divided by disease sever-
ity, age of onset, or responsiveness to treatment. We
deﬁned category 1 as the neonatal, classical, severe, or
early-onset forms of the diseases. We deﬁned category
2 as the later-onset, chronic, or milder forms of the dis-
eases. Some diseases have such mild variations that
they would not necessarily be detected or treated with-
out newborn screening; we deﬁned these as category 3
(Table 2 and Supplementary Table S1). In patients, the
symptoms and outcomes associated with each disease
variation are not mutually exclusive, but for the pur-
poses of this analysis, only three distinct categories
were modeled. For diseases with more than three rec-
ognized variations, variations were grouped based on
patient outcome.
Sensitivity, Speciﬁcity, and Positive Predictive Rate
We assumed that all positive MS/MS test results are
repeated on the original sample to conﬁrm the result,
which increases the positive predictive rate of screen-
ing. Nevertheless, because the repeated MS/MS test
does not occur on an independently taken blood
spot, the possibility of incorrect indication due to
biological variation, poor sample collection, and sam-
ple contamination does not change. To account for
this, the speciﬁcity of the repeated MS/MS test was
reduced.
We assumed that the average positive predictive
rate of an expanded Ontario newborn screening
program would be 20%, similar to the California
Newborn Screening trial (a pilot program) [28]. In
addition, the positive predictive rates of tyrosinemia
and MCADD have been reported as 2% [29] and 87%
[28], respectively. Using these known positive predic-
tive rates and holding the sensitivity of the test con-
stant, we estimated the speciﬁcity of the second MS/
MS test. There are diseases, such as MCADD, where
the screening test may identify patients in whom the
disease may never develop symptomatically. In this
analysis, we segregated these patients into category 3
and assumed that although they would never develop
the disease they are treated.
Health Beneﬁts
Mortality rates were estimated from the 2000 World
Health Organization Life Table for Canada [30].
Information regarding incremental mortality for per-
sons with metabolic diseases were collected from the
literature where available and when not available was
estimated by experts (Table 2). Health beneﬁts are
expressed in terms of changes in life-years (LYs) of sur-
vival associated with a given screening program.
Start-Up Costs
Based on manufacturer-estimated MS/MS throughput
of approximately 50,000 samples per year (Waters
Corporation, Mississauga, Ontario, Canada), esti-
mated machine downtime for maintenance, and
approximately 130,000 births per year [31], we esti-
mated that Ontario would require three mass spec-
trometers. Sample quotations were acquired from
PerkinElmer, Inc. (Woodbridge, Ontario, Canada) and
Waters Corporation for all the capital equipment
required to start an MS/MS facility. The total cost
depended on the company, as well as the brand of MS/
MS, autosampler, and gas generation system selected.
Training costs, computers and analysis software, and
5 years of full-service maintenance are included in
Table 1 Summary of key assumptions
• Screening can be carried out on any subset of the 21 diseases considered in this analysis.
• All diseases are grouped into three levels of severity: (1) neonatal, classical, severe, or early onset forms of the disease; (2) later-onset, chronic, or milder 
forms of the disease; and (3) mild variations that would not be detected or treated without newborn screening.
• Patients in the ﬁrst two categories would eventually be diagnosed clinically.
• Patients in the third category have the same life expectancy at birth as members of the general population.
• All initially positive screening results are conﬁrmed with a second tandem mass spectrometry (MS/MS) analysis before the patient is contacted.
• Positive results from MS/MS testing are conﬁrmed with other technologies before a ﬁnal diagnosis is made.
• While waiting for conﬁrmation, all patients receive 3 months of treatment, three appointments with a metabolic specialist, one appointment with a 
social worker, and one appointment with a genetic counselor. Patients receiving dietary therapy also receive three appointments with a registered 
dietitian.
• Start-up and operating costs were estimated using quotations provided by two manufacturers of MS/MS equipment.
• Hospital-related costs were obtained from case-costing at the London Health Sciences Center, London, Ontario.
• All costs are expressed in 2004 Canadian dollars.
• Future costs and beneﬁts are discounted at 3%.
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these estimates, with total costs before ﬁnancing of
$19,650, $78,325, and $412,500, respectively. We
assumed that the capital equipment would have a 5-
year life, with no salvage value. The annual cost,
assuming that the capital costs would be ﬁnanced for
5 years at 6.5% annual interest [32] and that payments
would be equally distributed over the 5 years, ranged
from $337,326 to $490,379 (Table 3).
Conﬁrmatory Testing
When both the initial and repeated MS/MS test results
are positive, the family is contacted so that treatment
can begin immediately and the MS/MS test result can
be conﬁrmed using a different diagnostic technology
on an independently taken blood sample. Some con-
ﬁrmatory tests are readily available in Ontario and the
Table 3 Base case values and costs of the screening program, health care, hospitalization, education, and social services. All costs
are presented in 2004 Canadian dollars
Parameter Base case Reference
Participation rate 98% [51]
Guthrie screening program
Bacterial inhibition assay sensitivity 98.50% [49]
Bacterial inhibition assay speciﬁcity 99.95% [49]
Cost per sample (averaged estimates of 70,000 and 100,000 samples per year), 
including a sample repeat rate of 2% 
$0.66 *
Cost of clinical diagnosis $4,389 ‡
Mass spectrometry screening program
Sensitivity (%)
Fatty acid β-oxidation disorders 100 [25,52]
Organic acidemias 100 [25]
Urea cycle disorders (not including CPS and OTC deﬁciencies) 95.54 [29]
Amino acidemias (except B6-responsive HCYS) 100 [7,53]
B6-responsive HCYS 38.7 [2]
Speciﬁcity (%)
Fatty acid β-oxidation disorders 99.95 [29]
Organic acidemias 99.98 [25,29]
Urea cycle disorders 99.67 [29]
Amino acidemias 99.95 [25,53]
Costs ($)
Annual equipment cost 490,380 See text
Staff expense per sample, two estimates were averaged for MS/MS operation in 
the Ontario provincial laboratory
0.85 †
Reagent and consumables per sample 13.46 §
Average per capita health care costs ($)
Average health care costs (>1 year) 5,211 [54]
Average health care costs (1–4 years) 800 [54]
Average health care costs (5–14 years) 693 [54]
Average health care costs (15–19 years) 1,089 [54]
Average health care costs (20–44 years) 1,825 [54]
Average health care costs (45–64 years) 4,244 [54]
Average health care costs (65–79 years) 7,736 [54]
Average health care costs (80+ years) 14,417 [54]
Hospitalizations ($)
Emergency room visit 1,167 See text
Inpatient hospitalization, patient under 10 years 2,055 See text
Inpatient hospitalization, patient over 10 years 1,765 See text
Additional health care services ($)
Initial call to schedule appointment (15-minute phone call with registered nurse) 7.03 [55]
Initial specialist consult (all presumptive positives) 122.00 [56]
Subsequent pediatrician and specialist appointments (per appointment) 73.85 [56]
Registered dietitian appointments (per 60 minute appointment) 75.96 [57]
Initial genetic counseling appointment (in the year of diagnosis) 238.20 [56]
Follow-up genetic counseling appointment (3 years after initial diagnosis) 100.90 [56]
Maintenance diagnostics ($)
Quantitative amino acid analysis 108 [58]
Urine organic acids 108 [58]
Abdominal ultrasound 339 [56,57]
Nondietary treatments ($)
Hemodialysis—initial acute 1,045.15 [56,57]
Hemodialysis—chronic or repeat 537.40 [56,57]
Liver transplant 67,965.85 [56,57]
Kidney transplant 32,593.30 [56,57]
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costs of those tests were estimated using the Ministry
of Health Schedule of Laboratory Fees [58]. Rare met-
abolic enzyme assays are, however, often performed
outside Canada because they are otherwise unavaila-
ble. We assumed that these tests would continue to be
performed outside of Canada.
Once an IEM is suspected through clinical presen-
tation, conﬁrmatory testing is also required. Neverthe-
less, the cost of that testing is not incurred until the
year of clinical diagnosis. In addition, other costs asso-
ciated with clinical diagnosis are also incurred in the
year of diagnosis. We estimated these costs to be
$4389 (the value of one hospital stay and two emer-
gency room visits with laboratory tests).
Based on personal experience, we assumed that, on
average, conﬁrmation test results would be available
within 3 months. During this period the patient and/or
patient’s family (depending on the age of the patient at
diagnosis) would receive three 60-minute appoint-
ments with a metabolic specialist, one 60-minute
appointment with a social worker, and one 2-hour
appointment with a genetic counselor. For diseases
that require nutritional counseling, the patient and/or
patient’s family would also have three 60-minute
appointments with a registered dietitian before conﬁr-
mation test results were available. In the sensitivity
analysis, we evaluated the effect of reduced quality of
life that parents may experience during this uncertain
3-month period, ranging from 0.97 to 0.99 annualized
[24].
Treatment
Once the patient and/or patient’s family receives con-
ﬁrmation of diagnosis, we assumed that the patient
would receive treatment and blood tests for therapeu-
tic monitoring and indications of disease/treatment
complications for the remainder of his/her life. We
also assumed that the patient and/or patient’s family
would receive a second appointment with a genetic
counselor 3 years after the initial diagnosis. Patients
and their families would have regular appointments
with metabolic specialists, dietitians, and social work-
ers. The regularity of these appointments varies with
age, severity of disease, ability to adhere to treat-
ment, and responsiveness to treatment (Supplemen-
tary Table S2).
Pharmaceutical treatments($)¶ (approximate annual cost)
Arginine (660 mg/kg/day) 41,063 Estimated
Ascorbic acid (100 mg/day) 30 [57]
Betaine (6 g/day) 73 Estimated
Carbamazepine (200 mg/day) 90 [59]
Cobalamin (1.5 mg/day) 1,700 [59]
Cysteine (6 g/day) 5,724 [57]
Glycine (375 mg/kg/day) 685 Estimated
L-carnitine (100 mg/kg/day) 7,565 [57]
MCT (120 ml/day) 4,380 [59]
Metronidazole (250 mg/day) 155 [59]
NTBC (1 mg/kg/day) 91,250 Estimated
Pyridoxine (300 mg/day) 82 [59]
Riboﬂavin (200 mg/day) 58 Estimated
Sodium-phenylbutyrate (500 mg/kg/day) 71,237 Estimated
Thiamine (500 mg/day) 3,980 [57]
Dietary treatments ($)
Elemental formula (year 0) 4,000 [60]
Elemental formula (1–8 years) 5,000 [60]
Elemental formula (8–16 years) 6,000 [60]
Elemental formula (over 16 years) 5,000 [60]
Low protein foods (1–8 years) 2,000 [60]
Low protein foods (>8 years) 3,500 [60]
Education and social services ($)
Standard education (5–18 years) 7,500 [61]
Additional classroom support 18,000 [62]
Advanced classroom support 27,000 [62]
Living in an assisted-living facility 18,000 See text
Living in an institutional facility 36,000 See text
Social worker appointments (per 60 minute appointment) 76.98 [57]
Discount rate for costs and beneﬁts 3%
Parameter Base case Reference
Table 3 continued
*Described as requiring approximately 0.15 full-time-equivalent (FTE) technician, 0.25 FTE technician II, and 0.15 FTE head technologist. (N. Lepage et al., unpublished)
†N. Lepage et al., unpublished.
‡We assumed that one hospital stay and two emergency visits with laboratory tests included would be required to clinically diagnose a patient with an inborn error of metabolism.
§PerkinElmer (Woodbridge, Ontario, Canada) sells a kit that combines all the reagents required for detection of amino acids and acylcarnitines, standards, and derivatizing agent
for $7.86 per clinical test. Waters Corporation (Mississauga, Ontario, Canada) did not have a price at the time of our analysis.
¶Approximate annual cost for a 25-kg individual using an average treatment regimen.
CPS, carbamoyl phosphate synthetase; HCYS, homocystinuria; MCT, medium chain triglycerideoil; NTBC, 2-(2-nitro-4-triﬂuoromethylbenzoyl)-1,3-cyclohexanedione; OTC,
ornithine transcarbamylase.
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Hospitalization
We estimated the total cost of hospitalization, length
of stay, and emergency room visits using the cost of
treating patients with metabolic diseases, acidosis, and
alkalosis at London Health Sciences Centre (LHSC)
[57]. We pooled the costing data for all the Interna-
tional Classiﬁcation of Diseases, 10th Edition (ICD-
10) codes included (ICD-10 codes deﬁning primary or
secondary diagnosis: E70.0–70.2, E71.3, E72.0–72.2,
E72.5, E72.8, E87.2, E87.3), and then divided them
by type of hospitalization: inpatient, 493 cases; and
emergency visits, 34 visits. The average cost of an
emergency department visit was $974. Inpatient hos-
pitalizations were further divided by age: less than
10 years, 45 cases; and more than 10 years, 448 cases.
The average lengths of stay were 12 and 16 days,
respectively. The average cost of an inpatient stay was
$1952 per day for patients less than 10 years of age
and $1675 per day for patients more than 10 years of
age. The average daily cost of all inpatient hospitali-
zations for all reasons at LHSC was $1314 [57]. Phy-
sician costs are billed directly to the Ministry of Health
and Long-Term Care (MOHLTC) and are not included
in the cost of hospital care. Using the Ontario
MOHLTC’s Schedule of Beneﬁts for Physician Services
[56], we estimated the cost of physician services to
bring the ﬁnal cost of an emergency department visit to
$1167, and of inpatient hospitalizations to $2055 and
$1765 per day.
Social Services and Education
We assumed that all families of infants who received a
diagnosis of an IEM receive 1 hour with a social
worker in the year of diagnosis and 1 hour in the sub-
sequent year. One study indicates that parents of
infants diagnosed via a screening program are better
able to cope with the challenges of the disease than
parents whose children are diagnosed clinically [63].
Therefore, in the base case we assumed that the 9%
reported in that study to have difﬁculty coping despite
early diagnosis and the 29% reported to have difﬁculty
coping after a child has been clinically diagnosed with
a metabolic disease [63] would continue to receive
1 hour of social work services per year until they are
18 years of age. In the sensitivity analysis, we tested a
range of other assumptions, including that social work
use is equal at the low rate (9% of patients each year),
equal at the high rate (29% of patients each year), and
eliminated for all groups.
For all disease states and outcomes, all school-age
children attend public school and, unless otherwise
noted, do not require special assistance. Information
regarding intelligence level and social and physical
development were acquired from secondary sources
and, when not available, expert opinion (Supplemen-
tary Table S2). Patients described as moderately dis-
abled were assumed to require additional classroom
support between ages 5 and 18 years, estimated to cost
$18,000 per year [62], and were assumed to live in an
assisted-living facility from age 18 until 75, at a cost of
$18,000 per year. We assumed that patients described
as severely disabled required advanced classroom sup-
port for more than 80% of the school day between ages
5 and 18 years, costing $27,000 per year [62], and that
they live in an institutional facility from age 18 until 75,
costing $36,000 per year. Although the copayment
structure in Ontario varies, depending on the patient’s
ability to pay, we estimated this to be the total cost
based on similarly styled, not-for-proﬁt US facilities.
Screening Program Strategies
Two program strategies were assessed: each disease
was assessed independently, and diseases were assessed
in bundles. Policymakers may choose to screen for any
one individual disease and so when assessed individu-
ally, the incremental cost of each disease included the
entire capital cost of investing in the MS/MS technol-
ogy, the variable cost of screening, and the cost of pro-
gram maintenance. One beneﬁt of MS/MS, however, is
that several diseases can be screened for at one time,
enabling policymakers to design a screening program
without incurring additional capital costs when addi-
tional diseases are considered. Diseases were bundled
into groups based on their individual cost-effectiveness
and sufﬁcient detail is provided such that the cost-
effectiveness of bundles not presented can be
determined.
Results
Screening by MS/MS for PKU Only
In the base case, changing technologies for PKU
screening costs an additional $2.26 million each year
and has an incremental cost-effectiveness ratio (ICER)
of $5,492,114 per LY gained (Table 4). Every 6 years
of screening using MS/MS would prevent one false
negative (0.17 fewer false negatives per year) and
0.412 LY will be gained by each birth cohort.
Screening by MS/MS for Other IEMs
The cost-effectiveness of screening for each disease
independently ranged from $221,719 to
$142,462,687 per LY gained (Fig. 2a, Table 4).
The four most cost-effective diseases to screen for
(HMG-CoA lyase deﬁciency, MCADD, methylmalonic
acidemia, and 3-methylcrotonyl-CoA carboxylase deﬁ-
ciency), assuming each is screened for independently,
have incremental costs ranging from $221,719 to
$266,991 per LY gained. Among all the diseases
assessed, these four diseases do not have the lowest
incremental costs, but they do have the largest incre-
mental LY gains.
Screening for MCADD alone has an ICER of
$253,161 per LY gained. This is higher than others
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have reported; however, those studies have only eval-
uated the incremental cost of adding MCADD to an
existing screening panel [7,23,34]. The incremental
cost of adding MCADD to a screening panel estimated
here ($62,798 per LY gained, Table 5) is consistent
with another reported estimate of $41,862 per quality
adjusted life-year (QALY) gained [23]. Other groups
have made different assumptions about the duration of
carnitine supplementation; if we make similar assump-
tions and stop carnitine treatment in all MCADD
patients at age 18 [23] or age 5 [7], the ICER of screen-
ing for MCADD becomes cost saving, consistent with
estimates ranging from $300 per LY gained to cost
saving [7,24,25].
Glutaric acidemia type II (GAII) is the least cost-
effective disease to screen for under base case assump-
tions. The total incremental cost of screening for just
GAII is $2.5 million, but each infant who receives a
diagnosis of GAII only gains 0.033 LY. This results in
an ICER of $142.5 million per LY gained.
Screening for Combinations of Diseases
Diseases were ranked in order of their incremental
cost-effectiveness, so that the most cost-effective
screening program, including the greatest number of
diseases, could be identiﬁed. The order and the cost-
effectiveness of adding additional diseases to a screen-
ing program are presented in Table 5.
Screening for PKU and three diseases will result in
ﬁve infants each year who will be diagnosed and
treated earlier and who will gain a total of 30 LYs.
Screening for PKU and 14 diseases will result in 92 LYs
gained across the 27 infants who will receive an early
diagnosis each year. Screening for all 21 diseases will
result in 32 early diagnoses each year and 107 LYs
gained across the cohort (Fig. 2b).
When we consider the marginal cost-effectiveness
of adding diseases to a screening program in which
PKU screening has absorbed all the ﬁxed costs, adding
the third disease (maple syrup urine disease) costs
$15,426 per LY gained. Adding the seventh disease
(glutaric acidemia type I) to the bundle costs $48,071
per LY gained and adding the 14th disease (carnitine/
acylcarnitine translocase deﬁciency) costs $95,000 per
LY gained. Although the average cost-effectiveness for
PKU and 15 diseases is less than $100,000 per LY
gained, the marginal cost-effectiveness of adding the
15th disease (tyrosinemia type I) is $309,409 per LY
gained.
The least cost-effective IEMs to screen for are those
that affect the urea cycle (arginemia, arginosuccinic
aciduria, and citrullinemia). This is largely due to a
Table 4 Incremental cost-effectiveness of each disease evaluated independently and a breakdown of incremental costs†, savings, and
life-years (LYs) gained per patient screened
Disease
Incremental
cost ($)
(including 
start-up*)
Incremental cost
($) (excluding
start-up)
Incremental 
LYs gained ($)
(×10−5)‡
ICER§ ($)
(including
start-up)
ICER ($) 
(excluding
start-up)
Fatty acid β-oxidation disorders
Carnitine transporter defect 19.89 1.52 3.59 554,039 42,340
Carnitine palmitoyl transferase I deﬁciency 19.92 1.55 1.67 1,192,814 92,814
Carnitine/acylcarnitine translocase deﬁciency 20.02 1.65 1.76 1,137,500 93,750
Carnitine palmitoyl transferase II deﬁciency 19.89 1.52 1.60 1,243,125 95,000
Very long-chain acyl-CoA dehydrogenase deﬁciency 19.97 1.60 4.32 462,269 37,037
Long-chain hydroxyl acyl-CoA dehydrogenase deﬁciency 20.00 1.63 1.88 1,063,830 86,702
Medium-chain acyl-CoA dehydrogenase deﬁciency 24.43 6.06 9.65 253,161 62,798
Glutaric acidemia type II 19.09 0.72 0.0134 142,462,687 5,373,134
Organic acidemias
HMG-CoA lyase deﬁciency 19.60 1.23 8.84 221,719 13,914
3-methylcrotonyl-CoA carboxylase deﬁciency 24.67 6.30 9.24 266,991 68,182
Glutaric acidemia type I 21.61 3.24 6.74 320,623 48,071
Isovaleric acidemia 19.12 0.75 1.25 1,529,600 60,000
Methylmalonic acidemia 19.40 1.03 7.64 253,927 13,482
Propionic acidemia 20.11 1.74 6.24 322,276 27,885
Urea cycle disorders
Arginemia 47.75 29.38 1.20 3,979,167 2,448,333
Arginosuccinic aciduria 62.89 44.52 3.09 2,035,275 1,440,777
Citrullinemia 60.81 42.44 2.42 2,512,810 1,753,719
Amino acidemias
Tyrosinemia type I 32.51 14.14 4.57 711,379 309,409
Homocystinuria 20.44 2.07 0.625 3,270,400 331,200
Maple syrup urine disease 19.24 0.87 5.64 341,135 15,426
Phenylketonuria and variants 17.41 −0.96 0.317 5,492,114 −302,839
*Program start-up and base operation costs (whether screening for one or more diseases) is $18.37 per infant.
†For additional detail, please see Supplementary Table S3.
‡i.e., ﬁrst row: “3.59” = 3.59 × 10−5 = 0.0000359.
§The incremental cost-effectiveness ratio (ICER) describes the incremental cost required to acquire the beneﬁt of 1 additional LY. It is calculated by dividing the total incremental
cost by the incremental LYs gained.
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low number of LYs gained combined with a high
incremental cost associated with treating patients
with sodium-phenylbutyrate. Urea cycle disorders fre-
quently result in death before a clinical diagnosis is
made. Although early diagnosis leads to enhanced sur-
vival in some cases, it also results in an expensive treat-
ment regimen. Combined screening for the urea cycle
disorders would cost $17.5 million and only detect 4.5
affected infants each year. Infants detected with urea
cycle disorders in one cohort will gain 8.7 LYs. The
ICER for screening for the three urea cycle disorders
included in this model is $2.0 million. Carbamoyl
phosphate synthetase deﬁciency and ornithine tran-
scarbamylase deﬁciency are not reliably detected by
MS/MS and so were not included in this analysis.
We varied each model parameter in a one-way sen-
sitivity analysis (Table 6 and Supplementary Table S4).
Birth volume variation across the year may produce
times when three mass spectrometers cannot supply
the timely results needed; however, substantial sensi-
tivity analysis on the cost of MS/MS shows that if a
fourth ($24.00 per sample) or even ﬁfth ($27.00 per
sample) instrument is required, the average cost-
effectiveness of a screening program including PKU
and 14 diseases is less than $85,000 per LY gained. The
model is most sensitive to MS/MS speciﬁcity. The ICER
of screening for PKU and 14 diseases is $173,100 per
LY gained when the speciﬁcity of the MS/MS test is
reduced by just 0.05% from the base case.
Four pessimistic scenarios were evaluated in which
both the sensitivity and speciﬁcity of MS/MS were
reduced in combination with increased costs and
reduced life expectancy. The incremental cost of
screening for PKU and 14 diseases increases to
$149,700 when all costs are increased by 50% and the
life expectancy of early diagnosed patients are reduced
Figure 2 Cost-effectiveness plane. (A) Incre-
mental costs and effectiveness for each disease if
screened for independently. Each square repre-
sents a screening program that screens for only
one disease and includes the full cost of the
screening technology, maintenance, and techni-
cian time. (B) Incremental costs and effective-
ness for bundles of diseases. Each square
represents a screening program that screens for
phenylketonuria (PKU) and subsequent diseases
reading left to right (as shown in Table 5 from
top to bottom). Incremental costs and life-years
gained are expressed per cohort of 130,000
babies. ARG, arginemia (arginase deﬁciency);
ASA, arginosuccinic aciduria; CAT, carnitine/
acylcarnitine translocase deﬁciency; CIT, citrul-
linemia (arginosuccinate synthase deﬁciency);
CPT1, carnitine palmitoyl transferase I deﬁ-
ciency; CPT2, carnitine palmitoyl transferase II
deﬁciency; CTD, carnitine transporter defect;
GA1, glutaric acidemia type I; GA2, glutaric
acidemia type II; HCYS, homocystinuria; HMG,
HMG-CoA lyase deﬁciency; IVA, isovaleric
acidemia; MCADD, medium-chain acyl-CoA
dehydrogenase deﬁciency; MMA, methylmalonic
acidemia; MS/MS, tandem mass spectrometry;
MSUD, maple syrup urine disease; PA, propri-
onic acidemia; VLCADD, very long-chain acyl-
CoA dehydrogenase deﬁciency; LCHADD, long-
chain hydroxyl acyl-CoA dehydrogenase deﬁ-
ciency; TYR1, tyrosinemia type I; 3-MCC, 3-
methylcrotonyl-CoA carboxylase deﬁciency.
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by 25%. Reductions in speciﬁcity have a signiﬁcant
impact on cost-effectiveness estimates in the pessimis-
tic scenarios.
Discussion
Changing screening technologies for PKU alone is not
cost-effective by currently accepted standards [64].
Nevertheless, a screening program including PKU and
14 diseases would have an incremental cost of less than
$70,000 per LY gained. Each disease being screened
for would have an incremental cost of less than
$100,000 per LY gained and the program would iden-
tify approximately 27 babies born with a treatable
metabolic disease in Ontario each year.
Some diseases will continue to have high mortality
rates despite the expansion of newborn screening
programs. Proper identiﬁcation of the cause of death,
however, will permit parents to seek genetic coun-
seling. Although many factors contribute to parental
decision-making, Read found that 56% of parents
who have a child with an inherited metabolic disease
wanted prenatal diagnosis in a future pregnancy, 10%
wanted to selectively terminate a future affected preg-
nancy, and 41% were already taking measures to pre-
vent future affected pregnancies [65]. These numbers
may vary across religious and cultural groups [66] as
well as with the severity of disease observed in the ﬁrst
child [67,68]. Accurate information may, however, aid
future decision-making.
Screening has been found to be cost-effective by
other research groups [7,20,23,24,69], although the
estimated incremental cost per LY gained varies
widely. Estimates for the addition of MCADD to an
existing screening program range from cost saving to
$41,862 per QALY [7,23–25]. One estimate of adding
a series of fatty acid oxidation disorders and organic
acidemias to a screening panel suggests a cost of
$15,252 per QALY [23]. Pollitt et al. estimated the
cost-effectiveness of screening for more than a dozen
individual IEMs as well as other diseases that can be
screened for at birth [7]. In contrast to our study, Pol-
litt et al. found several diseases, such as methylmalonic
acidemia and propionic acidemia, to be more cost-
effective than we did. Severe forms of these diseases,
however, were excluded from their analysis because
they were deemed “untreatable.”
Others have stopped short of presenting a detailed
economic analysis of each IEM because they have
found screening for MCADD alone “to be cost-
effective enough to justify the adoption of MS/MS
screening” [23]. In contrast, we believe that the vari-
ation in MS/MS sensitivity and speciﬁcity to identify
other diseases, different costs of treatment, and differ-
ent potential beneﬁts from early intervention indicate
that the addition of each disease requires independent
evaluation. Having already justiﬁed investment in MS/
MS technology does not indicate that it is economical
to use MS/MS for every potential use. This article indi-
cates that, in fact, having already invested in MS/MS,
Table 5 Incremental costs, savings, life-years gained, and cost-effectiveness of adding each disease to a screening strategy in the base
case scenario per patient screened
Screening 
programs Disease added
Incremental
cost of 
adding the
disease to
the bundle
($)
Incremental
cost of 
bundle ($)
Life-years
gained 
adding the
disease to
the bundle
(×10−4)*
Life-years
gained 
for the 
bundle
(×10−4)
ICER of 
adding the
disease to
the bundle
($)
ICER 
of the
bundle
($)
PKU Phenylketonuria 17.41 17.41 0.0317 0.0317 5,492,114 5,492,114
PKU + 1 + Methylmalonic acidemia 1.03 18.44 0.764 0.796 13,482 231,746
PKU + 2 + HMG-CoA lyase deﬁciency 1.23 19.67 0.884 1.68 13,914 117,104
PKU + 3 + Maple syrup urine disease 0.87 20.54 0.564 2.24 15,426 91,545
PKU + 4 + Propionic acidemia 1.74 22.28 0.624 2.87 27,885 77,693
PKU + 5 + Very long-chain acyl-CoA dehydrogenase deﬁciency 1.60 23.88 0.432 3.30 37,037 72,370
PKU + 6 + Carnitine transporter defect 1.52 25.40 0.359 3.66 42,340 69,424
PKU + 7 + Glutaric acidemia type I 3.24 28.64 0.674 4.33 48,071 66,102
PKU + 8 + Isovaleric acidemia 0.75 29.39 0.125 4.46 60,000 65,931
PKU + 9 + Medium-chain acyl-CoA dehydrogenase deﬁciency 6.06 35.45 0.965 5.42 62,798 65,373
PKU + 10 + 3-methylcrotonyl-CoA carboxylase deﬁciency 6.30 41.75 0.924 6.35 68,182 65,782
PKU + 11 + Long-chain hydroxyl acyl-CoA dehydrogenase deﬁciency 1.63 43.38 0.188 6.53 86,702 66,384
PKU + 12 + Carnitine palmitoyl transferase I deﬁciency 1.55 44.93 0.167 6.70 92,814 67,043
PKU + 13 + Carnitine palmitoyl transferase II deﬁciency 1.65 46.58 0.176 6.88 93,750 67,726
PKU + 14 + Carnitine/acylcarnitine translocase deﬁciency 1.52 48.10 0.160 7.04 95,000 68,346
PKU + 15 + Tyrosinemia type I 14.14 62.24 0.457 7.49 309,409 83,045
PKU + 16 + Homocystinuria 2.07 64.31 0.0625 7.56 331,200 85,098
PKU + 17 + Arginosuccinic aciduria 44.52 108.83 0.309 7.87 1,440,777 138,351
PKU + 18 + Citrullinemia 42.44 151.27 0.242 8.11 1,753,719 186,564
PKU + 19 + Arginemia 29.38 180.65 0.120 8.23 2,448,333 219,550
PKU + 20 + Glutaric acidemia type II 0.72 181.37 0.00134 8.23 5,373,134 220,389
*i.e., ﬁrst row: “0.0317” = 0.0317 × 10−4 = 0.00000317.
ICER, incremental cost-effectiveness ratio.
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screening for arginosuccinate lyase deﬁciency, citrul-
linemia, arginemia, and GAII are not cost-effective
even when the costs and beneﬁts are averaged across
all diseases in the screening program.
This model includes a broad societal perspective,
including not only the costs of screening and initial
assessment, but also the downstream costs of coun-
seling, education, and long-term tertiary care. This
model also assumes that all patients would treat their
disease for life; however, most patients on restricted
diets relax the restrictions in young adulthood [70]. In
Ontario, the current provincially insured beneﬁts for
these patients end at age 18 years. Prohibitive cost has
also been identiﬁed as one barrier to access to treat-
ment with respect to maternal PKU [71]. Restricted
diet for life is the only way to prevent neurological
deterioration from classical PKU [72–74] and maternal
PKU [75]. The incremental cost-effectiveness of dietary
treatment for life versus ceasing treatment in young
adulthood has not been evaluated.
Our analysis assesses outcomes in LYs gained
because there is insufﬁcient information in the litera-
ture to generate quality of life adjustments for all the
diseases and disease states discussed here. Addition-
ally, there are several unresolved problems using
QALY measurements in infants and children [76–
82]. Using QALYs instead of LYs gained may overes-
timate the cost-effectiveness of screening when the
quality of life in the additional years is low. Con-
versely, using QALYs instead of LYs gained may
result in an underestimation of the cost-effectiveness
when the number of additional years gained is low
but the quality of life in all years is improved. The
latter is likely the case with MCADD, for example.
Given the lack of peer-reviewed long-term data in
this area [83], the reported challenges of generating
credible and legitimate quality of life estimates for
infants and children [76–82], and evidence that qual-
ity of life assessments do not substantially alter the
cost-effectiveness of interventions [84], we decided to
Table 6 Summary of sensitivity results*
Parameter Base case Range tested
Marginal cost-effectiveness ratio ($ per LY gained) Average cost 
effectiveness ratio 
for PKU + 14 
diseasesPKU + 3 PKU + 7 PKU + 14
Base case result for reference $15,426 $48,071 $95,000 $68,346
Incidence: See Table 2 50–150% of 
Base Case
$36,000–$12,200 $61,700–$44,400 $164,900–$79,300 $109,900–$54,400
Mass spectrometry screening program:
All disease sensitivity See Table 3 Less 10% $29,700 $64,500 $897,800 $221,100
All disease speciﬁcity See Table 3 Less 1% $352,700 $572,000 $2595,600 $668,346
Costs (total test cost per infant) $18.37 $10–$50 $15,426–$15,700 $48,071–$48,000 $93,900–$95,100 $56,300–$113,500
Potential legal costs:
If every false negative was 
reimbursed some value in 
year 10
$0 $0–$5,000,000 $15,426 $48,071 $95,000 $63,300
If every clinical diagnosis was 
reimbursed for lack of earlier 
detection some value in year 10
$0 $0–$500,000 Cost saving Cost saving $9,100 Cost saving
Life expectancy: See Table 2 All reduced 
25%
$13,700 $66,200 $369,100 $112,800
All increased 
25%
$21,100 $34,700 $73,200 $46,800
All + 20 years
(max 78 years)
$20,600 $33,600 $58,600 $41,300
Quality of life for parents during uncertain diagnosis period
(applies to all IEM cases and
false positives for 3 months)
1 LY 0.99 QALY
(annualized)
$16,900 $49,300 $134,400 $73,500
1 LY 0.97 QALY
(annualized)
$20,700 $70,100 $694,400 $104,000
Discount rate 3% 0–9% $16,000–$31,400 $43,300–$82,000 $78,000–$255,000 $51,400–$130,800
Pessimistic scenarios:
1. Reduced sensitivity (10%) and 
reduced speciﬁcity (1%) for all 
diseases $2,610,600
$407,600 $539,000 $2,610,600 $770,100
2. All costs increased (50%) $7,400 $23,600 $48,300 $46,600
3. All costs increased (50%) and 
reduced life expectancy (25%)
$20,400 $98,900 $552,600 $149,700
4. Reduced sensitivity (10%), 
reduced speciﬁcity (1%), 
increased costs (50%), and 
reduced life expectancy (25%)
$751,500 $1,687,700 $13,268,800 $2,042,500
*Please see Supplementary Table S4 for additional information.
IEM, inborn error of metabolism; PKU, phenylketonuria; QALY, quality-adjusted life-year.
Cipriano et al.94
mediate this limitation through extensive sensitivity
analysis.
This study relied on the costing information from
LHSC, a large academic hospital. Costs provided did
not include physician costs, and a fee for service com-
pensation method was assumed. These costs and this
compensation scheme may not be representative of
other hospitals. Nevertheless, LHSC does have signif-
icant experience treating patients with metabolic dis-
ease as it is the tertiary care center responsible for
patients with metabolic disease from a large geo-
graphic region.
This  study  does  not  consider  the  potential  need
for additional investments in infrastructure or human
resource training outside of the MS/MS laboratory.
The large volume of potential positives that will result
from the MS/MS screen may overwhelm the current
IEM specialists and treatment support structures.
Coordination of communication, follow-up evalua-
tion, and treatment support services may need addi-
tional management and investment.
There is strong support for the idea that screening
would result in longer, healthier patient lives [5–
9,25,26,33,37,40,41,47,48,85–97]. The data in this
article, however, relied on several studies with a small
number of cases and on expert opinion. The literature
on disease incidence, life expectancy, and dependence
on social services by these populations is not robust.
Robust data is unattainable in an unscreened popula-
tion and only good program management will eventu-
ally reveal the outcomes of screening.
Our analysis suggests that in order for an MS/MS
screening program to be cost-effective several diseases
must be screened for in a single bundle. It is, however,
not cost-effective to include all possible diseases in that
bundle. The incremental cost of screening per LY gained
can be optimized by screening for PKU and nine dis-
eases, including methylmalonic acidemia, HMG-CoA
lyase deﬁciency, maple syrup urine disease, propionic
acidemia, very long-chain acyl-CoA dehydrogenase
deﬁciency, carnitine transporter defect, glutaric
acidemia type I, isovaleric acidemia, and MCADD.
Using a threshold of $100,000 per LY gained, we ﬁnd
moderate evidence to support the adoption of screening
for PKU and 14 additional diseases [64]. Therefore,
consistent with more than half of North American
jurisdictions that have already initiate MS/MS screen-
ing including British Columbia, Saskatchewan, and
Nova Scotia, there is evidence to support Ontario’s
adoption of expanded newborn screening.
Source of ﬁnancial support: This study was funded by the
Natural Science and Engineering Research Council of
Canada.
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